Article Text

Download PDFPDF

EP259/#509  Genetic counseling and testing for epithelial ovarian cancer in a diverse patient population
  1. Kee-Hwan Kim1,
  2. Judy Hayek2,
  3. Cheyenne Aker3,
  4. Anjile An4,
  5. Peilin Zhang5,
  6. Constantine Gorelick6 and
  7. Margaux Kanis6
  1. 1NewYork-Presbyterian Brooklyn Methodist Hospital, Obstetrics and Gynecology, Brooklyn, USA
  2. 2SUNY Downstate Health Sciences University, Gynecologic Oncology, Brooklyn, USA
  3. 3Weill Cornell Medicine, Obstetrics and Gynecology, New York, USA
  4. 4Weill Cornell Medicine, Division of Biostatistics, New York, USA
  5. 5NewYork-Presbyterian Brooklyn Methodist Hospital, Pathology, Brooklyn, USA
  6. 6NewYork-Presbyterian Brooklyn Methodist Hospital, Gynecologic Oncology, Brooklyn, USA


Introduction Genetic testing is recommended for women diagnosed with epithelial ovarian cancer. Results inform surveillance, familial testing, and treatment. We report genetic counseling and testing rates at a tertiary care center with a large minority population.

Methods Retrospective cohort study of patients with newly diagnosed epithelial ovarian, fallopian tube, peritoneal cancer between January 2014 and June 2022 at the NewYork-Presbyterian Brooklyn Methodist Hospital.

Results 144 patients identified. Mean age at diagnosis was 63 years (SD:13). 51% identified as white, 36% black, 3.5% Asian, 9% other/unknown; 9% were Hispanic and 26% were non-English speaking. 104 (72%) patients received genetic counseling and 99 (69%) received subsequent genetic testing. 95% of those that underwent genetic counseling underwent testing. The genetic counseling and testing rates were not influenced by race, ethnicity, language, insurance type, BMI, family history of cancer. It was associated with significant difference by cancer stage (p<0.01). There was a significant upward trend of proportion of patients that received genetic counseling from 47% in 2015 to 100% in 2022 (p<0.01). Most genetic counseling was performed by a gynecologic oncologist (93%) as opposed to a genetic counselor (6.7%). Overall, 12 (8.3%) patients were BRCA+.

Conclusion/Implications Genetic counseling and testing rates within this diverse study population proved to be at least twice as high as the national average of 10–30%, with an increasing year-to-year trend. There were no disparities observed, in contrast to previously published data. BRCA mutation detection was in line with established prevalence within ovarian cancer, indicating adequate screening.

© 2023 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2023 ASCO Annual Meeting. All rights reserved.’

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.